Astrazeneca (AZN) Interest Expenses (2009 - 2026)

Astrazeneca's Interest Expenses history runs 18 years deep, the most recent figure standing at -$393.0 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 12.61% year-over-year to -$393.0 million; the TTM figure through Mar 2026 stood at -$1.8 billion (down 4.29% YoY), while the FY2025 annual figure was $1.7 billion, down 2.76% from the prior year.
• Interest Expenses was -$393.0 million for Q1 2026 at Astrazeneca, up from -$484.0 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of -$311.0 million in Q2 2022 to a low of -$484.0 million in Q4 2025.
• Historically, Interest Expenses has averaged -$401.2 million across 5 years, with a median of -$413.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Interest Expenses tumbled 1344.44% in 2022, then advanced 15.5% in 2025.
• A 5-year view of Interest Expenses shows it stood at -$360.0 million in 2022, then decreased by 23.61% to -$445.0 million in 2023, then advanced by 3.6% to -$429.0 million in 2024, then retreated by 12.82% to -$484.0 million in 2025, then rose by 18.8% to -$393.0 million in 2026.
• The last three Interest Expenses figures came in at -$393.0 million (Q1 2026), -$484.0 million (Q4 2025), and -$434.0 million (Q3 2025), per Business Quant data.